Paradromics builds an industry-leading brain-computer interface (BCI) platform that records brain activity at the highest possible resolution: the individual neuron. The company's AI algorithms decode this massive amount of brain data, enabling the seamless translation of thought into treatments for neurological conditions. Paradromics' Connexus BCI system helps people who are unable to speak due to ALS, spinal cord injuries, and stroke to communicate independently through digital devices by translating neural signals into synthesized speech, text, and computer control.
The company's high-speed BCI platform is designed for long-term daily use and has achieved industry-leading data rates of 200+ bits per second. With FDA Breakthrough Device Designations and approval for clinical trials, Paradromics is advancing toward human studies of its implantable technology. The platform extends beyond communication restoration to address a wide range of unmet medical needs, including paralysis, movement disorders, chronic pain, addiction, depression, and other mental health conditions. Paradromics has raised over $140 million in funding with support from DARPA and NIH to develop its scalable neural interface technology.
